Heart Failure Reviews最新文献_第7页

Mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF). 心力衰竭伴射血分数保留（HFpEF）的运动不耐受机制。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-03-13 DOI: 10.1007/s10741-025-10504-3

Brandon Pecchia, Roy Samuel, Vacha Shah, Emily Newman, Gregory T Gibson

{"title":"Mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF).","authors":"Brandon Pecchia, Roy Samuel, Vacha Shah, Emily Newman, Gregory T Gibson","doi":"10.1007/s10741-025-10504-3","DOIUrl":"10.1007/s10741-025-10504-3","url":null,"abstract":"Exercise intolerance is a well-established symptom of heart failure with preserved ejection fraction (HFpEF) and is associated with impaired quality of life and worse clinical outcomes. Historically attributed to diastolic dysfunction of the left ventricle, exercise intolerance in HFpEF is now known to result not only from diastolic dysfunction, but also from impairments in left ventricular systolic function, left atrial pathology, right ventricular dysfunction, and valvular disease. Disorders of heart rate and rhythm such as chronotropic incompetence and atrial fibrillation have also been implicated in exercise intolerance in this population. Pathologic changes to extra-cardiac organ systems including the respiratory, vascular, hormonal, and skeletal muscle systems are also thought to play a role in exercise impairment. Finally, comorbidities such as obesity, inflammation, and anemia are common and likely contributory in many cases. The role of each of these factors is discussed in this review of exercise intolerance in patients with HFpEF.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"777-789"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart and brain interactions in heart failure: pathophysiological mechanisms and clinical perspectives. 心力衰竭的心脏和大脑相互作用：病理生理机制和临床观点。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-03-18 DOI: 10.1007/s10741-025-10505-2

Sotiria Liori, Angelos Arfaras-Melainis, Vasiliki Bistola, John Parissis

{"title":"Heart and brain interactions in heart failure: pathophysiological mechanisms and clinical perspectives.","authors":"Sotiria Liori, Angelos Arfaras-Melainis, Vasiliki Bistola, John Parissis","doi":"10.1007/s10741-025-10505-2","DOIUrl":"10.1007/s10741-025-10505-2","url":null,"abstract":"Heart failure (HF) is a complex and debilitating syndrome that affects millions of people worldwide. In addition to the syndrome-related functional limitations, such as exercise intolerance and dyspnea, patients frequently suffer from various comorbidities. Neuropsychiatric conditions, including autonomic dysfunction, cognitive impairment, and depression, are important albeit underrecognized comorbidities in HF. Autonomic dysfunction, which is expressed as sympathetic predominance and decreased parasympathetic tone, is a key contributor to HF progression. Depression and cognitive impairment are highly prevalent in HF patients, affecting adherence to medical treatment and increasing morbidity and mortality risk. Stress cardiomyopathy, a usually reversible form of left ventricular dysfunction triggered by emotional or physical stress, is another clinical manifestation of the interplay between the heart and the brain. Early recognition and management of these comorbidities in HF patients are crucial for improving outcomes. This narrative review provides an overview of the pathophysiological mechanisms linking HF and brain disorders and discusses clinical perspectives of heart-brain interactions in the context of HF.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"791-800"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing the lymphatic system. 利用淋巴系统

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2024-10-15 DOI: 10.1007/s10741-024-10449-z

Barbara Ponikowska, Marat Fudim, Gracjan Iwanek, Robert Zymliński, Jan Biegus

{"title":"Harnessing the lymphatic system.","authors":"Barbara Ponikowska, Marat Fudim, Gracjan Iwanek, Robert Zymliński, Jan Biegus","doi":"10.1007/s10741-024-10449-z","DOIUrl":"10.1007/s10741-024-10449-z","url":null,"abstract":"Heart failure (HF) is a growing concern, with significant implications for mortality, morbidity, and economic sustainability. Traditionally viewed primarily as a hemodynamic disorder, recent insights have redefined HF as a complex systemic syndrome, emphasizing the importance of understanding its multifaceted pathophysiology. Fluid overload and congestion are central features of HF, often leading to clinical deterioration and hospital admissions, with the role of the lymphatic system previously largely overlooked, partly due to diagnostic challenges and visualization difficulties. With the advancement of those techniques, pathophysiological changes occurring in the lymphatic system during HF, such as enlargement of the thoracic duct and the increased lymphatic flow, are now becoming apparent. This emerging research has begun to uncover the interplay between lymphatic dysfunction and HF, suggesting novel therapeutic targets. Advances in molecular biology, such as targeting vascular endothelial growth factor and promoting lymphangiogenesis, hold promise for improving lymphatic function and mitigating HF complications. This article provides a comprehensive overview of the evolving landscape of lymphatic system-targeted therapies for HF. It explores various intervention levels, from mechanical lymphatic decongestion to pharmaceutical interactions and lymphatic micro-circulation, offering insights into future directions and potential clinical implications for HF management.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"673-683"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12165986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Worsening heart failure: progress, pitfalls, and perspectives. 心衰恶化：进展、陷阱和前景。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-02-20 DOI: 10.1007/s10741-025-10497-z

Cândida Fonseca, Rui Baptista, Fátima Franco, Brenda Moura, Joana Pimenta, Pedro Moraes Sarmento, José Silva Cardoso, Dulce Brito

引用次数: 0

Electronic health record nudges to optimize guideline-directed medical therapy for heart failure. 电子健康记录推动优化心力衰竭的指导医学治疗。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-03-19 DOI: 10.1007/s10741-025-10503-4

Michael A Fuery, Katherine A Clark, Nikhil V Sikand, Sara R Tabtabai, Sounok Sen, F Perry Wilson, Nihar R Desai, Tariq Ahmad, Marc D Samsky

{"title":"Electronic health record nudges to optimize guideline-directed medical therapy for heart failure.","authors":"Michael A Fuery, Katherine A Clark, Nikhil V Sikand, Sara R Tabtabai, Sounok Sen, F Perry Wilson, Nihar R Desai, Tariq Ahmad, Marc D Samsky","doi":"10.1007/s10741-025-10503-4","DOIUrl":"10.1007/s10741-025-10503-4","url":null,"abstract":"Electronic health record (EHR) alert nudges are emerging as a valuable tool for improving heart failure (HF) management, particularly by enhancing the use of guideline-directed medical therapy (GDMT). These nudges, integrated as clinical decision support (CDS) tools within EHR systems, provide real-time, evidence-based prompts that assist clinicians in making informed treatment decisions at critical moments in patient care. Studies have shown that targeted alerts can improve GDMT adherence and outcomes. Designing effective nudges requires aligning alert content, timing, and format with clinician workflows to reduce alert fatigue and enhance usability. Furthermore, involving clinicians in the design process helps ensure alerts are relevant, context-sensitive, and integrated smoothly into practice. EHR nudges present an innovative approach to bridging quality gaps in HF care by encouraging timely interventions and adherence to best practices, but their efficacy depends on thoughtful implementation. Future research is needed to refine alert strategies, optimize their impact on clinical outcomes, and explore their role across diverse healthcare settings, ultimately advancing the potential of EHR nudges to improve HF care quality.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"771-776"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart failure with preserved ejection fraction and atrial fibrillation: epidemiology, pathophysiology, and diagnosis interplay. 心力衰竭保留射血分数和心房颤动：流行病学、病理生理学和诊断的相互作用。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-01-24 DOI: 10.1007/s10741-025-10488-0

Veraprapas Kittipibul, Carolyn S P Lam

引用次数: 0

Myeloperoxidase inhibition in the landscape of anti-inflammatory therapies for heart failure with preserved ejection fraction: the ENDEAVOR trial. 髓过氧化物酶抑制在保留射血分数的心力衰竭抗炎治疗中的应用：ENDEAVOR试验

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-02-25 DOI: 10.1007/s10741-025-10498-y

Veraprapas Kittipibul, Andrew P Ambrosy, Stephen J Greene

引用次数: 0

Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art. 塞马鲁肽在心力衰竭和动脉粥样硬化性心血管疾病中的应用：最新进展。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-07-01 Epub Date: 2025-03-31 DOI: 10.1007/s10741-025-10506-1

Nikolaos Theodorakis, Magdalini Kreouzi, Maria Nikolaou

{"title":"Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art.","authors":"Nikolaos Theodorakis, Magdalini Kreouzi, Maria Nikolaou","doi":"10.1007/s10741-025-10506-1","DOIUrl":"10.1007/s10741-025-10506-1","url":null,"abstract":"Cardiovascular disease mortality rates, which had steadily declined over decades, are now plateauing or reversing due to the global rise in type 2 diabetes mellitus (T2DM) and obesity. These cardiometabolic conditions contribute significantly to atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease. Among emerging pharmacological treatments, glucagon-like peptide-1 receptor agonists, particularly semaglutide, have shown benefits beyond diabetes and obesity management, including cardioprotective and renoprotective effects. This state-of-the-art review comprehensively analyzes current evidence from clinical trials, identifies critical insights, and outlines research directions regarding semaglutide use in HF, ASCVD, and diabetic nephropathy. In ASCVD, semaglutide has demonstrated significant reductions in major adverse cardiovascular events, supported by findings from meta-analyses of trials in patients with T2DM and the SELECT trial for patients without T2DM. In a prespecified analysis of the SELECT trial, semaglutide demonstrated significant reductions in cardiovascular mortality and HF hospitalizations for patients with HF and ASCVD. In HF with preserved ejection fraction and mildly reduced ejection fraction, semaglutide improved symptoms, physical function, natriuretic peptide levels, echocardiographic parameters, and HF hospitalizations, as shown in the STEP-HFpEF program and a pooled analysis of trials. Furthermore, evidence from the FLOW trial underscores semaglutide's renal and cardiovascular benefits in diabetic nephropathy, irrespective of body mass index. While these findings suggest semaglutide's efficacy in cardiorenal diseases, gaps in evidence remain, including the need for event-driven trials in HF populations without ASCVD and irrespective of obesity. Future research should address these gaps, which could potentially update guideline recommendations.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":"801-816"},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of atrial fibrillation in patients with heart failure with preserved ejection fraction. 保留射血分数的心力衰竭患者心房颤动的处理。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-06-29 DOI: 10.1007/s10741-025-10536-9

Paula Rambarat, Adam D DeVore, Daniel B Mark, Tristam D Bahnson, Jonathan Piccini

引用次数: 0

A concise guide of contemporary cardiovascular imaging practices to differentiate athlete's heart in the gray zone. 当代心血管成像实践的简明指南，以区分运动员心脏在灰色地带。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-06-27 DOI: 10.1007/s10741-025-10541-y

Efstathios D Pagourelias, Styliani Ouzouni, Panagiotis Salmatzidis, Theocharis Sargiannidis, Eleni Tsiouli, Dimitrios Ntelios, Evangelia Kouidi, Vasileios P Vassilikos

{"title":"A concise guide of contemporary cardiovascular imaging practices to differentiate athlete's heart in the gray zone.","authors":"Efstathios D Pagourelias, Styliani Ouzouni, Panagiotis Salmatzidis, Theocharis Sargiannidis, Eleni Tsiouli, Dimitrios Ntelios, Evangelia Kouidi, Vasileios P Vassilikos","doi":"10.1007/s10741-025-10541-y","DOIUrl":"https://doi.org/10.1007/s10741-025-10541-y","url":null,"abstract":"Athlete's heart comprises various structural and functional adaptations, imposed by systematic training and intended to serve the increased needs of the body during exercise. In most cases, athletic cardiac remodeling presents mild characteristics that are easily distinguishable from pathologic entities. However, common inherited cardiomyopathies such as hypertrophic, dilated, or arrhythmogenic may also affect athletes or athletic individuals, while athlete's heart in a more pronounced form (frequently called \"gray\" zone) should be distinguished from early stages of the above-mentioned cardiomyopathies. Based on these assumptions, cardiovascular imaging remains the key process that should be applied to accurately differentiate between normal and abnormal phenotypes, facilitating thus pre-participation screening along with early detection and handling of underlying cardiomyopathies. Recent advances in both echocardiography and cardiovascular magnetic resonance offer new diagnostic potentials, making, however, \"method\" and \"time\" selection rather complicated. The aim of this review is to provide a short and comprehensive guide for differentiating athlete's heart in the gray zone from cardiomyopathies, encompassing all contemporary tools of imaging modalities into easily applicable and hierarchically appropriate algorithms.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0